This article is written for licensed healthcare providers who are building or expanding hormone optimization services. It is educational in nature and does not constitute a clinical protocol or prescribing guidance. Providers should rely on their clinical training, current literature, and qualified medical director oversight when developing patient-specific hormone programs. The regulatory information in this guide reflects the landscape as of mid-2025 — providers should confirm current FDA guidance on specific compounds before prescribing.
The Three Modalities — A Clinical Map
The terms BHRT, TRT, and "peptide therapy" are used loosely in the market — sometimes interchangeably, sometimes incorrectly, and often without clear patient communication about what is actually being prescribed. For providers building a legitimate hormone optimization program, precision matters. These are distinct clinical tools with different mechanisms, regulatory frameworks, and patient populations.
BHRT in Depth — Women's Hormone Optimization
BHRT in its full form addresses the estrogen, progesterone, and testosterone decline of perimenopause and menopause. The clinical and market case for a well-structured women's BHRT program is strong: demand is high, patient retention is excellent (hormone patients return for follow-up on a structured schedule), and many markets are underserved by providers willing to do the clinical work required.
The "bioidentical" distinction matters to patients more than it changes the prescribing fundamentals. Bioidentical estradiol and progesterone are available in FDA-approved forms (Estrace, Prometrium, Divigel, among others) and through compounding pharmacies. For providers new to BHRT, FDA-approved formulations are a lower-compliance-risk starting point than compounded protocols.
The hormone cascade — what you're replacing and why
Perimenopause begins, on average, 4–8 years before the final menstrual period — typically in the mid-40s. The hormonal changes are not a sudden cliff but a years-long fluctuation: estrogen swings erratically before declining, progesterone drops earlier and more steeply, testosterone declines gradually from the mid-30s onward. By the time most women seek help, they are dealing with multiple simultaneous deficiencies.
- Estradiol (E2) — primary driver of vasomotor symptoms (hot flashes, night sweats), vaginal atrophy, mood instability, bone density loss, and cardiovascular risk changes. The most symptom-impactful hormone to replace.
- Progesterone — required to oppose estrogen in women with an intact uterus (unopposed estrogen increases endometrial cancer risk). Also has independent effects on sleep, anxiety, and fluid retention. Often replaced as micronized progesterone (Prometrium or compounded).
- Testosterone (women) — frequently the most under-addressed component. Women produce testosterone in the adrenal glands and ovaries; production declines significantly by menopause. Replacement at appropriate female doses addresses libido, energy, body composition, and cognitive clarity. Prescribing testosterone in women requires specific knowledge of dosing ranges — female doses are typically 10–20% of male doses.
- DHEA — adrenal androgen precursor that declines with age in both sexes. Intravaginal DHEA (Prasterone/Intrarosa) is FDA-approved for dyspareunia. Systemic DHEA supplementation is available OTC in the US, complicating the prescriber-patient discussion.
Providers launching BHRT programs should have a structured intake that includes: comprehensive symptom assessment, morning hormone labs (estradiol, FSH, LH, testosterone, SHBG, DHEA-S, thyroid panel), relevant risk stratification (personal and family history of breast cancer, clot history, cardiovascular risk), and documented clinical decision-making for why the specific hormone regimen was chosen. Symptom-only prescribing without lab documentation is a compliance and liability exposure.
TRT in Depth — Men's Testosterone Optimization
Men's TRT is a high-demand, high-retention service category. Testosterone declines approximately 1–2% per year after age 30, and the symptoms of hypogonadism — fatigue, decreased libido, body composition changes, mood and cognitive changes — are underdiagnosed and undertreated in primary care. Independent hormone clinics and medspas have filled a genuine gap.
TRT is a Schedule III controlled substance regardless of formulation. Any provider prescribing testosterone needs a valid DEA registration. The prescribing process requires documented labs — not a patient report of "feeling low T" — and a monitoring protocol for ongoing safety.
Delivery methods compared
The delivery method chosen affects patient adherence, efficacy, estrogen conversion rate, and the monitoring requirements. Each has tradeoffs:
- Intramuscular injection (testosterone cypionate/enanthate) — most common, lowest cost, widest peak-to-trough fluctuation. Weekly injections reduce peak-trough swing versus every-2-week dosing. Patient self-injection is feasible and common; in-clinic injection is used where patients prefer it or for weekly monitoring visits.
- Subcutaneous injection — smaller volume, slower absorption, more stable levels than IM. Growing in popularity. Similar monitoring requirements to IM.
- Testosterone pellets — implanted SQ every 3–6 months; provides steady-state levels without daily/weekly administration. Higher upfront cost; dose adjustment requires waiting until current pellets metabolize. Revenue model: procedure-based rather than monthly Rx.
- Topical gel/cream — convenient, non-invasive, but has transfer risk to partners and children. Less predictable absorption. Common as a starting point for new patients hesitant about injections.
- Nasal gel (Natesto) — FDA-approved, preserves endogenous LH/FSH to a greater degree than other formulations; relevant for fertility-preserving considerations. Three-times-daily dosing limits adherence.
Estradiol management in TRT
Testosterone aromatizes to estradiol. In some patients — particularly those with higher adipose tissue — testosterone supplementation raises estradiol to symptomatic levels (gynecomastia, water retention, mood changes). Managing this requires estradiol monitoring and, when indicated, aromatase inhibitor prescribing. Anastrozole is the most commonly used AI in TRT contexts. Providers running TRT programs should have a documented protocol for estradiol management — including when to treat, target estradiol ranges, and how to titrate the AI.
A patient on testosterone cypionate injection protocol requires: initial labs + consultation, 6–8 week follow-up labs + visit, then quarterly monitoring visits with labs. Annual recurring revenue per TRT patient (visits + labs if in-house + medication markup): typically $1,200–$2,400/year depending on program structure. A practice with 100 active TRT patients has a predictable $120k–$240k annual recurring revenue baseline before any new patient acquisition. The retention rate is high — patients who feel better on TRT are highly adherent to follow-up protocols.
Peptide Therapy — What's Legal, What Isn't, and Why It Matters
Peptide therapy is the most complex category from a regulatory standpoint, and the landscape shifted significantly between 2022 and 2025. Providers who built peptide programs based on what was available through compounding pharmacies in 2021 may be operating with compounds that are now restricted or outright prohibited.
The FDA's authority over peptides flows primarily through its oversight of compounding pharmacies. Many peptides were previously available as bulk drug substances from 503A and 503B compounding pharmacies. The FDA has progressively narrowed what can be compounded, placing several widely-used peptides on restricted lists.
BPC-157, TB-500 (thymosin beta-4), CJC-1295, Ipamorelin, and several other GH secretagogues have been placed on the FDA's list of bulk drug substances that cannot be used in compounding as of 2023–2025. Providers who obtained these compounds from compounding pharmacies prior to these restrictions should not assume continued availability is lawful. Work with a pharmacy compliance attorney to audit your current formulary before seeing patients for these compounds. The enforcement risk is real — DEA and FDA have conducted inspections of compounding pharmacies supplying these substances.
Currently prescribable peptides (as of mid-2025)
Side-by-Side: BHRT vs TRT vs Peptides
| Attribute | BHRT | TRT | Peptide Therapy |
|---|---|---|---|
| Primary patient population | Peri/post-menopausal women; aging men (andropause) | Men 30–65 with documented hypogonadism; women with low-T | Broad — weight loss, sexual wellness, anti-aging, recovery |
| DEA scheduling | When testosterone included: Schedule III. Estrogen/progesterone: non-scheduled Rx. | Schedule III — DEA registration required for all prescribers | GLP-1s: Rx, non-scheduled. PT-141: non-scheduled. Most others: varies or restricted. |
| Required labs before initiation | Comprehensive hormone panel, metabolic, lipid, thyroid; mammogram and Pap current | Testosterone (total + free), SHBG, LH, FSH, estradiol, PSA, CBC, CMP, lipids | GLP-1: A1c, fasting glucose, CMP, lipids. PT-141: cardiovascular screen. Others: varies. |
| Monitoring frequency | 6–8 weeks post-initiation, then every 3–6 months; annual mammogram recommendation | 6–8 weeks post-initiation (labs + visit), then quarterly; hematocrit monitoring ongoing | GLP-1: quarterly labs + visits. PT-141: BP check. Sermorelin: IGF-1 monitoring. |
| Revenue model | Quarterly visits + labs + ongoing Rx fills. Strong annual recurring revenue per patient. | Quarterly visits + labs + medication markup or in-clinic injection fees | Monthly program fees (GLP-1); per-use (PT-141); varies by compound and delivery |
| Regulatory complexity | Moderate — multiple agents, risk stratification required | Moderate — Schedule III, DEA required, estradiol management | High — FDA enforcement active; compound-by-compound review required |
| Patient retention rate | Very High — patients on effective BHRT are highly adherent | Very High — symptomatic improvement drives long-term compliance | Varies — GLP-1 retention depends on outcomes and cost management |
| Medical director requirement | Required for RN-operated practices; NPs in AZ can self-direct with appropriate training | Required for RN-operated; AZ NPs can self-direct; DEA registration always required | Same as above; medical director must have specific knowledge of compounds being directed |
| Training available through Beso | Yes — Hormone Optimization course | Yes — Hormone Optimization course | Yes — covered in Hormone Optimization + Sexual Wellness courses |
Lab Monitoring Reference
The monitoring table below is a reference for providers building hormone programs. It represents standard-of-care monitoring as practiced in well-run hormone clinics — not minimum legal standards. More frequent monitoring may be warranted based on individual patient risk factors, dosing changes, or symptom changes.
| Program | Baseline (Pre-Initiation) | 6–8 Weeks Post-Start | Ongoing (Stable Patient) |
|---|---|---|---|
| Women's BHRT (full panel) | E2, FSH, LH, Total T, Free T, SHBG, DHEA-S, Progesterone, TSH, Free T3/T4, CMP, CBC, Lipids, hs-CRP | E2, Total T, Free T, SHBG, Progesterone (if cycling); symptom reassessment | Full panel every 6 months; mammogram annually; Pap per guidelines |
| Men's TRT (injection) | Total T (AM), Free T, SHBG, LH, FSH, E2, PSA, CBC (hematocrit), CMP, Lipids, TSH | Total T (trough timing), Free T, E2, Hematocrit; dose adjustment if needed | Full panel every 3–6 months; PSA annually (40+); hematocrit every 3 months first year |
| GLP-1 (semaglutide/tirzepatide) | A1c, fasting glucose, CMP, lipids, TSH, CBC; BMI documented; caloric intake baseline | Weight, fasting glucose, GI symptoms assessment; A1c at 12 weeks | A1c quarterly; CMP, lipids every 6 months; annual comprehensive review |
| PT-141 (Vyleesi) | BP, cardiovascular risk assessment; HSDD documentation (validated tool recommended) | BP check; symptom response and side effect review | BP at each encounter; annual cardiovascular reassessment |
| Sermorelin (if available) | IGF-1, GH if accessible; CBC, CMP, fasting glucose; symptom documentation | IGF-1; symptom response; glucose tolerance check | IGF-1 every 6 months; glucose tolerance annually |
Building a Compliant Hormone Program
A compliant hormone program is not just about prescribing lawfully — it's about having documented systems that can survive scrutiny from a state board, an insurance audit (if billing insurance), or a DEA inspection. Providers who run hormone programs informally — symptom-based prescribing, inconsistent lab monitoring, undocumented dosing rationale — are exposed even when their patient outcomes are excellent.
The minimum structural requirements for a compliant hormone program:
- Documented protocols for each modality offered. Not just "we do TRT" — a written protocol specifying intake labs, diagnostic criteria, starting dose ranges, monitoring schedule, and criteria for discontinuation or referral.
- Qualified medical director oversight with documented experience in the specific modalities offered. A medical director who has never managed TRT or BHRT patients cannot meaningfully oversee those services.
- DEA registration for any provider prescribing controlled substances (testosterone, any other Schedule II/III/IV agent).
- Compounding pharmacy compliance audit. Before prescribing any compounded hormone or peptide, confirm the pharmacy's 503A/503B status, obtain their list of currently lawful compounds, and document that review. Do not assume prior availability equals current legality.
- Informed consent documentation specific to each hormone modality — including risks of exogenous testosterone, estrogen's risk profile in applicable patient populations, and any off-label use disclosure.
- Chart documentation standards. Each visit should document: current symptoms, current dose, current labs, clinical reasoning for any dose changes, and patient response. Thin charts with no clinical reasoning are a compliance liability.
The hormone optimization market rewards providers who treat it as the clinical discipline it is — not a supplement-adjacent wellness offering, not a DTC telehealth volume play. The practices that build loyal, high-retention hormone patient populations are the ones that spend time on the intake process, stay current on the regulatory landscape, document their clinical reasoning, and have medical director oversight that actually brings expertise to the table. The market is large enough for providers who do this well to build genuinely excellent practices. The compliance and training infrastructure to do it correctly is the baseline requirement, not a competitive differentiator.